Press Release: Recyte Therapeutics : ESI BIO - a Division of BioTime, Inc. Launches New Research Technology Platform, VascuNet Pericyte Co-Culture Assay

ALAMEDA, Calif.--(BUSINESS WIRE)--ESI BIO (esibio.com), the stem cell products division of BioTime, Inc., announced today the release of its most recent technology platform designed to give researchers new standardized in vitro assays with greater physiological relevance and accuracy. The VascuNet Pericyte Co-Culture Assay provides a stable, clinically relevant angiogenesis model not currently obtainable with other vascular network systems. This breakthrough technology in angiogenesis assays w